When Time Is Follicle: Diagnosing Alopecia Areata

August 6, 2025

Upadacitinib (Rinvoq, AbbVie) in Severe AA: Explore the Topline Phase 3 Data

July 31, 2025

U.S. FDA Fast-tracks Nektar Therapeutics’ Rezpegaldesleukin for Severe-to-Very-Severe AA

July 29, 2025

Topical Botanical Shows Promise in AA: Here’s What To Know

July 23, 2025

Sun Pharma Launches Deuruxolitinib (Leqselvi) for Severe Alopecia Areata

July 14, 2025

Low-dose Doxycycline Curbs Symptoms of Lymphocytic Scarring Alopecia, Minus the Side Effects of Higher Doses

March 18, 2025

Lilly’s Baricitinib Yields High Rates of Hair Regrowth in Adolescents with AA: A Q & A With Brittany Craiglow, MD

March 8, 2025

Thermo Fisher Scientific Launches International CorEvitas Adolescent AA Clinical Registry

February 7, 2025

Alys Pharmaceuticals on the Move: FDA Clears IND for Phase 2a Trial of ALY-101 in AA

February 4, 2025

Veradermics Raises $75 Million in Series B Financing; Initiates Phase 2/3 Trial for Hair Loss

December 11, 2024

Fall Clinical News: Deuruxolitinib Provides Long-lasting Benefit in AA

October 25, 2024

Reviewing the EADV Data: Deuruxolitinib in Alopecia Areata

October 1, 2024